Fludarabine
Links shared publicly online about this topic
Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial : The Lancet Oncology
thelancet.com — “Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. By - Dr Thomas Elter MD, Prof Liana Gercheva-Kyu...” View full resource at thelancet.com
Most Recently Shared on October 11, 2011 at 1:45 pm By:
David Flores - Einstein College of Medicine Medical School
RT @TheLancet: New combination treatment prolongs lives of patients with the most common form of leukaemia http://t.co/b9KjH5RB #Oncology
Fludarabine Provides OS Advantage vs Chlorambucil in Previously Untreated CLL
clinicaloptions.com — “Fludarabine Provides OS Advantage vs Chlorambucil in Previously Untreated CLL” View full resource at clinicaloptions.com
Most Recently Shared on December 12, 2009 at 9:44 pm By:
Fludarabine Provides OS Advantage vs Chlorambucil in Previously Untreated CLL http://bit.ly/5LgDhj
ingentaconnect Fludarabine/prednisone: Agranulocytosis and fatal gastric haemorr...
ingentaconnect.com — “ingentaconnect Fludarabine/prednisone: Agranulocytosis and fatal gastric haemorr...” View full resource at ingentaconnect.com
Most Recently Shared on December 22, 2010 at 12:36 am By:
Fludarabine/prednisone: Agranulocytosis and fatal gastric haemorrhage in an elderly patient: case report: (Sourc... http://bit.ly/gvpsgU
Fludarabine, alemtuzumab extended PFS by 7 months in CLL | HemOncToday
hemonctoday.com — “Fludarabine combined with alemtuzumab improved PFS for patients with chronic lymphocytic leukemia compared with fludarabine alone, according to” View full resource at hemonctoday.com
Most Recently Shared on October 12, 2011 at 8:36 pm By:
HemOnc Today Oncology and Health News
#Fludarabine, #alemtuzumab extended PFS by 7 months in CLL http://t.co/7rqW7TQK
IngentaConnect Fludarabine: Rhodococcus equi infection (first report) leading to...
ingentaconnect.com — “IngentaConnect Fludarabine: Rhodococcus equi infection (first report) leading to...” View full resource at ingentaconnect.com
Most Recently Shared on August 24, 2010 at 11:15 am By:
Fludarabine: Rhodococcus equi infection (first report) leading to pneumonia, and CD4-lymphopenia in an elderly pat... http://bit.ly/ci1Rgx
GSK and Genmab announce topline results from the concluded pivotal trial of Arzerra (ofatumumab) in fludarabine and alemtuzumab refractory chronic lymphocytic leukemia
gsk.com — “GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today top line results from the concluded pivotal trial of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL).” View full resource at gsk.com
Most Recently Shared on August 9, 2010 at 9:10 pm By:
eyeonfda Pharma and Health Lawyer
GSK & Genmab - resultsof pivotal trial Arzerra (ofatumumab) in fludarabine & alemtuzumab refr chron lymphocytic leukemia http://ow.ly/2ncoe
Bendamustine, but not fludarabine, exhibits a low ... [J Cancer Res Clin Oncol. 2009] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 18 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on January 27, 2010 at 4:10 pm By:
Preliminary info on #lymphoma drugs stem cell toxicity: Bendamustine versus Fludarabine http://bit.ly/aOgmrR
First Line Therapy With Fludarabine Compared to Chlorambucil Does Not Result in a Major Benefit for Elderly Patients With Advanced Chronic Lymphocytic Leukemia - OncologySTAT
oncologystat.com — “Blood. 2009 Jul 15 - Fludarabine produced a higher CR rate than chlorambucil in elderly patients with CLL but no overall survival advantage.” View full resource at oncologystat.com
Most Recently Shared on August 3, 2009 at 8:49 pm By:
OncologySTAT Health Site and Oncology
Top Story of the Week: First-Line Fludarabine Not Superior to Chlorambucil in Elderly Patients With CLL http://tinyurl.com/n6gfwh
Pixantrone in Combination with Fludarabine, Dexamethasone and Rituximab Produces High Rates of Complete Remissions in Patients with Relapsed or Refractory Indolent Non-Hodgkins Lymphoma - Drugs.com MedNews
drugs.com — “- Results published in Cancer Cell Therapeutics, Inc. ( CTI ) (NASDAQ and MTA CTIC) announced the publication of results posted in the online journal of Cancer” View full resource at drugs.com
Most Recently Shared on June 17, 2011 at 1:04 pm By:
Drugs and Devices OW OW Health
Pixantrone in Combination with Fludarabine, Dexamethasone and Rituximab Produces High Rates of Complete Re... http://bit.ly/l7cg8P #drug
Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease - Full Text View - ClinicalTrials.gov
clinicaltrials.gov — “Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease - Full Text View - ClinicalTrials.gov” View full resource at clinicaltrials.gov
Most Recently Shared on January 28, 2010 at 9:10 pm By:
UK Clinical Trial w/ cord blood trnsplnt for Hl & NHL, following combo chemo & radiation. http://bit.ly/cZ9nA1
Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712
jco.ascopubs.org — “Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712” View full resource at jco.ascopubs.org
Most Recently Shared on April 18, 2011 at 1:04 am By:
G Garcia-Manero Internist, Oncologist, Physician, and Doctor
CALGB9271 confirms MD Anderson results with chemoimmunotherapy in CLL... http://fb.me/Gp0L5rlW
Multivariate Analysis of Response and Survival After Treatment With Clofarabine, Cytarabine, and G-CSF Priming (GCLAC) in Relapsed/Refractory Acute Myeloid Leukemia: Comparison With Prior Experience Using Fludarabine and Cytarabine Combination Regimens -
oncologynurseadvisor.com — “Pamela S. Becker, MD, PhD, at University of Washington in Seattle, Wash., and colleagues conducted a study that indicated priming with clofarabine, cytarabine, and granulocyte colony-stimulating factor (G-CSF) (GCLAC) is active in relapsed and refractory acute myeloid leukemia (AML). Results of this study were presented at the 52nd American Society of Hematology Meeting and Exposition.” View full resource at oncologynurseadvisor.com
Most Recently Shared on December 5, 2010 at 4:32 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Multivariate Analysis of Response and Survival After Treatment With Clofarabine, Cytarabine… http://goo.gl/fb/vRLof
FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
drugs.com — “Rituxan (rituximab) is used to treat Chronic Lymphocytic Leukemia. Includes Rituxan side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on February 22, 2010 at 11:41 pm By:
FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia - http://bit.ly/960vQR
US FDA Approves Rituxan/MabThera For The Most Common Type Of Adult Leukemia
medicalnewstoday.com — “Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for people” View full resource at medicalnewstoday.com
Most Recently Shared on February 20, 2010 at 4:06 pm By:
US FDA Approves Rituxan/MabThera For The Most Common Type Of Adult Leukemia http://mnt.to/3xV7 #lymphoma #leukemia
Genentech And Biogen Idec Receive A Complete Response From The FDA For Rituxan For Chronic Lymphocytic Leukemia
medicalnewstoday.com — “Genentech, inc., a wholly-owned member of the roche group (six: ro, rog; otcqx: rhhby), and biogen idec (nasdaq: biib) announced today that the u.s. food and drug administration (fda) issued a com” View full resource at medicalnewstoday.com
Most Recently Shared on November 20, 2009 at 9:20 am By:
Genentech And Biogen Idec Receive A Complete Response From The FDA For Rituxan For Chronic Lymphocytic Leukemia.. http://tinyurl.com/yhx227f
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
David Flores - Einstein College of Medicine
Albert Einstein College of Medicine. Biomedical research, medical education & clinical advances. Tweeting: David Flores, Paul Moniz,Deirdre Branley, Kim Newman.
-
Lymphomation.org
Lymphomation.org/Patients Against Lymphoma -- Providing support and timely access to evidence-based information on lymphomas and their treatment.
-
OrganizedWisdom GI
Organizing gastroenterology and digestion resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement
